GT Biopharma, Inc. (GTBP) [Rocket]

Overview

GT Biopharma, Inc. (GTBP)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/22/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/15/2023	4	Breen Michael Martin (Executive Chairman/Interim CEO) has filed a Form 4 on GT Biopharma, Inc.
08/15/2023	4	Ohri Manu (CFO & Secretary) has filed a Form 4 on GT Biopharma, Inc.
08/07/2023	10-Q	Quarterly Report for the period ended June 30, 2023
07/05/2023	8-K	Quarterly results
05/15/2023	10-Q	Quarterly Report for the period ended March 31, 2023
05/05/2023	DEFA14A	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	115.0	18.9	0.0	0.0	0.0	0.0	0.0	0.1
Revenue growth	508.2%					-100.0%	-55.7%	-83.4%
Cost of goods sold	0.0	0.0	-52.6	0.0	0.0	0.0	0.0	0.1
Gross profit	115.0	18.9	52.6	0.0	0.0	0.0	0.0	0.0
Gross margin	100.0%	100.0%					100.0%	6.6%
Selling, general and administrative	47.9	6.3	9.8	12.5	134.5	8.4	8.0	2.4
Research and development	9.6	0.5	1.7	9.1	1.1	1.0	1.0
EBITA	57.5	12.1	41.1	-21.6	-135.6	-9.4	-8.9	-2.4
EBITA margin	50.0%	64.2%					-33063.0%	-3891.8%
Amortization of intangibles								0.0
EBIT	57.5	12.1	41.1	-21.6	-135.6	-9.4	-8.9	-2.4
EBIT margin	50.0%	64.2%					-33063.0%	-3927.9%
Pre-tax income	-58.0	-28.3	-38.6	-259.2	-144.2	9.8	-32.7	-23.5
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-58.0	-28.3	-38.6	-259.2	-144.2	9.8	-32.7	-23.5
Net margin	-50.4%	-149.6%					-121207.4%	-38506.6%

Diluted EPS	($2.06)	($6.45)	($11.42)	($5.16)	($8.60)	$119.91	($13.67)	($10.09)
Shares outstanding (diluted)	28.2	4.4	3.4	50.2	16.8	0.1	2.4	2.3

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.